LAUSR

Lifestyle interventions have shown to reverse hyperglycemia to normoglycemia. However, most interventions are cost-intensive. Formula diets have shown to improve glycemic control and be cost-effective. We, therefore, hypothesized that adding a low-carbohydrate formula diet to a low-intense lifestyle intervention is superior in reversing prediabetes than lifestyle intervention alone. In this predefined subanalysis of a multicenter RCT (ACOORH study (no. NIHR CRN 3571)) including a total of n=463 obese subjects, overweight persons (n=141, BMI: >27 kg/m²) with prediabetes (defined as HbA1c: 5.7-6.4%) were randomized (1:2) into either a lifestyle intervention control group (CON, n=45) or a formula diet-based lifestyle intervention group (INT, n=96). Both groups were equipped with telemonitoring devices, received information on healthy diet and were instructed to increase physical activity. Additionally, INT received a low-carbohydrate, soy-protein-rich product (Almased®) substituting three meals/day (~1200 kcal) within the first week. During weeks 2-4, participants replaced two meals/day and during weeks 5-26 only one meal/day was substituted (1300-1500 kcal/day). Follow-up was performed after 52 weeks. Intention-to-treat analyses were performed. Nine and 8 persons of CON and INT (20% vs. 8%; P Disclosure S. Martin: Consultant; Self; Almased Wellness GmbH, AstraZeneca, Lilly Diabetes. W. Banzer: None. A. Berg: Research Support; Self; Almased Wellness GmbH. K. Braumann: None. D. Fuhrer: Research Support; Self; Almased Wellness GmbH. M. Halle: Advisory Panel; Self; Merck Sharp & Dohme Corp. Research Support; Self; Novartis AG. Speaker9s Bureau; Self; Amgen Inc., AstraZeneca, Berlin-Chemie AG, Daiichi Sankyo Company, Limited, Merck Sharp & Dohme Corp., Novartis AG, Pfizer Inc., Sanofi. D. McCarthy: None. M. Pinget: None. G. Predel: None. H. Toplak: Advisory Panel; Self; Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Mylan, Novartis AG, Novo Nordisk A/S, Sanofi. Research Support; Self; Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Novartis AG, Novo Nordisk A/S, Sanofi. Speaker9s Bureau; Self; Amgen Inc., Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Mylan, Novo Nordisk Inc., Sanofi. Funding Almased Wellness GmbH